- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01202955
Pilot Study of Tolcapone in Smokers
September 10, 2018 updated by: University of Pennsylvania
Pilot Study of Tolcapone Effects on Abstinence-Induced Cognitive Symptoms in Smokers
The goals of this within-subject pilot study are: (1) assess the feasibility and safety of administering the Catechol-O-Methyl-Transferase (COMT) inhibitor, tolcapone, to smokers, and (2) explore whether tolcapone may reduce abstinence-induced cognitive and affective symptoms that promote relapse.
A secondary exploratory goal is to assess whether these effects may be more pronounced in smokers who carry a high risk COMT genotype for smoking relapse: COMT val/val.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Despite decades of research to develop pharmacotherapies for nicotine dependence (ND), with current FDA approved medications (bupropion, varenicline and NRTs) the majority (>60%) of smokers relapse in the first year following treatment (Lerman, Patterson et al. 2005; Tonstad, Tonnesen et al. 2006).
Testing novel medications that may reduce abstinence symptoms that prompt smoking relapse is a plausible route to identifying new treatments for nicotine dependence.
The goals of this within-subject pilot study are: (1) assess the feasibility and safety of administering the Catechol-O-Methyl-Transferase (COMT) inhibitor, tolcapone, to smokers, and (2) explore whether tolcapone may reduce abstinence-induced cognitive and affective symptoms that promote relapse.
A secondary exploratory goal is to assess whether these effects may be more pronounced in smokers who carry a high risk COMT genotype for smoking relapse: COMT val/val.
Sixteen smokers (8 met/met genotype and 8 val/val genotype) who meet study eligibility criteria will complete two 10-day medication periods: one while taking tolcapone and one while taking placebo (order counterbalanced).
The testing session will occur on day 7 of each medication phase and include three computerized tasks.
Participants will be asked to refrain from smoking for at least 14 hours (overnight) prior to the testing day in each medication phase.
There will be a 3-day medication taper on days 8-10 of each medication period, followed by a washout period of at least 7 days between medication periods.
The main outcomes to be evaluated are participant enrollment and retention, side effects, and performance on computerized tasks.
Positive results from this pilot study would provide a basis for a larger scale investigation to assess the efficacy of tolcapone as a medication that ameliorates abstinence induced neurocognitive symptoms in smokers.
Study Type
Interventional
Enrollment (Actual)
19
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy as determined by a responsible physician, based on a medical evaluation including history, physical and psychiatric examination, laboratory tests, liver function monitoring.
- Smokers who are between 18 and 55 years of age and have an IQ greater than 90.
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions, listed in the consent form.
- Based upon self-report, subjects must smoke >10 cigarettes/day and be interested in quitting smoking in the next 6 months (i.e., treatment-seekers).
- Women of childbearing potential must consent to using a medically accepted method of birth control (e.g., condoms and spermicide, oral contraceptive, Depo-provera injection, contraceptive patch, tubal ligation).
Exclusion Criteria:
Smoking Behavior
- Use of chewing tobacco or snuff
- Current enrollment or plans to enroll in another smoking cessation program in the next month
- Plan to use other nicotine substitutes or smoking cessation treatments in the next month
- Provide a baseline carbon monoxide (CO) reading < 10ppm
Alcohol/Drug Exclusion Criteria
- History of substance abuse and/or currently receiving treatment for substance abuse (e.g., alcohol, opioids, cocaine, marijuana, MDMA/ecstasy, or stimulants)
- Current alcohol consumption that exceeds >14 standard drinks/week for men and >7 standard drinks/week for women over the last 6 months
Medication Exclusion Criteria
Current use or recent discontinuation (within last 4-weeks) of any medication including the following:
Any form of psychotropic medications including:
- antipsychotics,
- atypical antipsychotics,
- mood-stabilizers,
- anti-depressants (tricyclics, SSRI's, MAOI's, nonselective MAOIs, Wellbutrin/Zyban),
- anti-panic agents,
- anti-obsessive agents,
- anti-anxiety agents, and
- stimulants (e.g., Provigil, Ritalin)
- Varenicline
- Medication for chronic pain
- Anti-coagulants (e.g., Warfarin)
- Any heart medications
- Daily medication for asthma
- Apomorphine, dobutamine, isoproterenol, levodopa, methyldopa, or sympathomimetic (e.g., albuterol, pseudoephedrine)
- Current use of any smoking cessation medication.
Medical Exclusion Criteria
- Women who are pregnant, planning a pregnancy, or lactating.
- History or current diagnosis of psychosis, major depression or bipolar disorder, schizophrenia, or any Axis 1 disorder as identified by the MINI.
- Serious or unstable disease within the past 6 months (e.g., cancer [except squamous cell carcinoma], heart disease, HIV, liver disease, Parkinson's disease).
- History of epilepsy or a seizure disorder.
- History or current diagnosis (last 6-months) of abnormal rhythms and/or tachycardia (>100 beats/minute); history or current diagnosis of chronic obstructive pulmonary disease (COPD), cardiovascular disease (stroke, angina, coronary heart disease), heart attack in the last 6 months, uncontrolled hypertension (SBP>150 or DBP>90)
- History of Kidney and/or liver failure (including transplant) or problems (e.g., cirrhosis); current liver disease or impairment.
- History or current diagnosis of hepatitis.
- Liver function tests more than 20% outside of the normal range.
- Allergies to the study medication, tolcapone (Tasmar).
- History of severe, uncontrolled muscle movements (e.g., uncontrolled jerking, twitching) or a certain severe muscle problem (rhabdomyolysis).
- Experience of dizziness or lightheadedness upon standing on a regular basis (i.e., daily).
Genetic Profile
- Individuals with the heterozygous genotype (val/met) on the catechol-methyl transferase (COMT) gene. (Note: this is a small pilot study comparing effects of Tolcapone on cognitive performance between val/val (n=8) individuals.) Future research done at our center will plan to include those carrying the val/met genotype.
- Individuals with the homozygous genotype, met/met, on the COMT gene. As of December 2008, the study has accrued 8 met/met participants. To balance the genotype groups, the study will recruit an equal number of participants with the val/val genotype on the COMT gene and not include any further participants with the homozygous, met/met genotype. Future research done at our center will plan to include those carrying the met/met genotype.
- Non-European ancestry as determined by self report at initial telephone screening; we expect there to be ethnic differences in allele frequencies for COMT; therefore, as of December 2008, to reduce ethnic admixture that could bias the genetic analysis of this small sample, the study will be restricted to individuals of European ancestry. All participants of non-European ancestry will be referred to other studies at our center.
General Exclusion
- Any medical condition or concomitant medication that could compromise participant safety or treatment, as determined by the Principal Investigator and/or Study Physician.
- Inability to provide informed consent or complete any of the study tasks as determined by the Principal Investigator and/or Study Physician.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
|
Active Comparator: Tolcapone
|
Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Eligible Participants Enrolled Who Completed the Study.
Time Frame: 30 days
|
Number of enrolled participants who complete the final study visit
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
N-back (Working Memory) Correct Reaction Time After Overnight Abstinence.
Time Frame: 30 days
|
To obtain preliminary data on the effects of Tolcapone on abstinence-induced neurocognitive deficits in abstinent smokers with differing COMT genotypes.
We examined reaction time differences on the n-back task between tolcapone and placebo treatment.
|
30 days
|
Correct Reaction Time During Attention Task Performance After Overnight Abstinence.
Time Frame: 30 days
|
We wanted to examine the effects of Tolcapone on the Continuous Performance Task (attention task) after overnight abstinence as compared to placebo.
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Caryn Lerman, PhD, University of Pennsylvania
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2008
Primary Completion (Actual)
May 1, 2009
Study Completion (Actual)
June 1, 2009
Study Registration Dates
First Submitted
August 19, 2010
First Submitted That Met QC Criteria
September 15, 2010
First Posted (Estimate)
September 16, 2010
Study Record Updates
Last Update Posted (Actual)
September 12, 2018
Last Update Submitted That Met QC Criteria
September 10, 2018
Last Verified
September 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 808250
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nicotine Dependence
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Nicotine Dependence | Tobacco Dependence | Smoking, Tobacco | Nicotine Use Disorder | Nicotine Dependence, Cigarettes | Smoking, Cigarette | Nicotine Dependence Tobacco Product | Tobacco; Use, Rehabilitation | Smoking (Tobacco) Addiction and other conditionsUnited States
-
University of California, San FranciscoNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)WithdrawnCardiovascular Risk Factor | Nicotine Dependence | Nicotine Dependence, Cigarettes | Nicotine Withdrawal | Tobacco ToxicityUnited States
-
University of VermontNational Institute on Drug Abuse (NIDA)CompletedNicotine Dependence, CigarettesUnited States
-
Freedom Laser, Inc.NST Consultants, Inc.Completed
-
University of VermontNational Institute of General Medical Sciences (NIGMS)CompletedNicotine Dependence, CigarettesUnited States
-
Milton S. Hershey Medical CenterCompleted
-
University of OsloCharles University, Czech Republic; The Research Council of NorwayRecruitingNicotine Dependence, CigarettesCzechia, Norway
-
University of OsloCharles University, Czech Republic; The Research Council of NorwayRecruiting
-
Duke UniversityNational Institute on Drug Abuse (NIDA)CompletedNicotine Dependence, CigarettesUnited States
-
Milton S. Hershey Medical CenterTerminatedNicotine Dependence, CigarettesUnited States
Clinical Trials on Tolcapone
-
Corino Therapeutics, Inc.Quotient SciencesCompletedHealthy VolunteersUnited Kingdom
-
University of JenaCompletedInter-conversion n-3 PUFA, Vegetarians
-
Sheppard Pratt Health SystemLieber Institute for Brain DevelopmentUnknownBrain Injuries | Brain Injuries, Traumatic | Brain Injury, ChronicUnited States
-
University of ChicagoCompleted
-
University of California, BerkeleyUniversity of California, San Francisco; Lawrence Berkeley National LaboratoryRecruitingExecutive Function | Decision Making | DopamineUnited States
-
SOM Innovation Biotech SAHospital Vall d'HebronCompleted
-
University of ChicagoRecruitingObsessive-Compulsive Disorder | OCDUnited States
-
University of PennsylvaniaNational Institute on Drug Abuse (NIDA)Completed
-
Uppsala UniversitySwedish Society for Medical Research; Swedish Parkinson's Disease FoundationCompleted
-
Yale UniversityNational Institute on Drug Abuse (NIDA); US Department of Veterans AffairsCompleted